Long-term therapy outcomes of CD19/22 CAR T-cell alone or with autologous stem cell transplantation for relapsed/refractory DLBCL [0.03%]
CD19/22 CAR-T细胞治疗或联合自体造血干细胞移植治疗复发/难治DLBCL的长期疗效分析
Xiaoying Zhang,Jue Wang,Na Wang et al.
Xiaoying Zhang et al.
We conducted a comparative analysis of the long-term efficacy and safety of two single-arm trials for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): CD19/CD22 chimeric antigen receptor (CAR19/22) T-cell cocktail therapy alon...
ID2 suppresses multiple myeloma cell proliferation by repressing the activity of the transcription factor TCF3 [0.03%]
ID2通过抑制转录因子TCF3的活性来抑制多发性骨髓瘤细胞增殖
Mariateresa Fulciniti,Yao Yao,Tommaso Perini et al.
Mariateresa Fulciniti et al.
Transcription factors and their cofactors are major and selective non-oncogene dependencies in multiple myeloma (MM) cells. By performing a gain-of-function perturbation screen in human MM cell lines, we identified the ID genes as putative ...
Acquired and Selected: Tracking Antigen Escape during T Cell-Redirecting Therapies in Multiple Myeloma [0.03%]
追加和选择：在多发性骨髓瘤中追踪T细胞重定向治疗过程中的抗原逃逸现象
Joseph Kauer,Niels Weinhold,Marc S Raab
Joseph Kauer
In this issue of Blood Cancer Discovery, Papadimitriou and colleagues implement a temporal workflow to monitor genomic antigen escape during BCMA- or GPRC5D-directed immunotherapy. Using chemotherapy-induced mutational signatures as barcode...
RNA Splicing as a Therapeutic Vulnerability in Therapy-Refractory Multiple Myeloma [0.03%]
耐药多发性骨髓瘤治疗中的RNA拼接脆弱性
Maxim I Maron,Omar Abdel-Wahab
Maxim I Maron
In this issue of Blood Cancer Discovery, Kamiya and colleagues identify aberrant RNA splicing as a targetable vulnerability in multiple myeloma. Using the RBM39 degrader indisulam, they show that therapeutic modulation of RNA splicing facto...
The Two Sides of Bispecific Antibodies in Multiple Myeloma: Where Trial Promise Meets Real-World Practice [0.03%]
双特异抗体在多发性骨髓瘤的两面性：临床试验与现实世界实践之间的差距
Sonja Zweegman,Febe Smits,Niels W C J van de Donk
Sonja Zweegman
The real-world effectiveness of the bispecific antibody (BsAb) teclistamab appears to be lower than the efficacy observed in pivotal registration trials. Understanding the drivers of this effectiveness - efficacy gap is essential for guidin...
Perspectives on Newly Diagnosed Myeloma Treatment and Emerging Challenges [0.03%]
新诊断多发性骨髓瘤治疗观点及面临的挑战
Cyrille Touzeau,Philippe Moreau
Cyrille Touzeau
This commentary explores new challenges in the management of newly diagnosed multiple myeloma and strategies for sustaining improvements in patient outcomes. We highlight the need for risk-adapted approaches, the potential future incorporat...
Timing genomic antigen loss in multiple myeloma treated with T-cell redirecting immunotherapies [0.03%]
用于T细胞重定向免疫疗法治疗的多发性骨髓瘤基因组抗原丢失的定时监测
Marios Papadimitriou,Sungwoo Ahn,Benjamin T Diamond et al.
Marios Papadimitriou et al.
Genomic antigen loss is a recurring mechanism of resistance to chimeric antigen receptor T-cell (CAR-T) and T-cell engagers (TCE) in relapsed/refractory multiple myeloma (RRMM). Yet, it remains unclear whether these events are acquired unde...
Ghayas C Issa,Sheng F Cai,Alex Bataller et al.
Ghayas C Issa et al.
Menin inhibitors are targeted therapies for the treatment of genetically defined subsets of acute leukemia. The menin inhibitor revumenib is currently approved for relapsed or refractory leukemia with rearrangement of lysine methyltransfera...
Identification of a CD138-negative therapy-resistant subpopulation in multiple myeloma with vulnerability to splicing factor inhibition [0.03%]
识别多发性骨髓瘤中CD138阴性的耐药亚群及其对剪接因子抑制的敏感性
Takahiro Kamiya,Masahiko Ajiro,Motohiko Oshima et al.
Takahiro Kamiya et al.
The molecular basis of therapy resistance in multiple myeloma (MM) remains poorly understood. Here, we performed single-cell RNA sequencing coupled with VDJ-targeted sequencing of highly purified primary MM cells from patient bone marrow. T...
A FABulous Couple: Adding PHENotype to GENotype Improves HMA/VEN Response Prediction in AML [0.03%]
遗传和表型的结合能改善AML患者HMA治疗反应预测能力
Simon Renders,Alexander Waclawiczek,Andreas Trumpp
Simon Renders
In a large retrospective multicenter study of patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax, Lachowiez and colleagues examine the interplay among genetic mutations, disease phenotype, and clinical o...